A 12-Month, Phase 4, Open Label, Multicenter, Trial to Assess the Efficacy and Safety of COMBIGAN in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Bimatoprost (Primary) ; Brimonidine/timolol (Primary)
- Indications Glaucoma; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Allergan
- 16 Jul 2017 Planned End Date changed from 1 Mar 2018 to 30 Jul 2018.
- 16 Jul 2017 Planned primary completion date changed from 1 Mar 2018 to 30 Jul 2018.
- 16 Jul 2017 Status changed from recruiting to active, no longer recruiting.